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0090-4295for lower urinary tract symptoms secondary to benign prostate hyperplasia using 3 different laser
fibers and 2 different laser energy modes.MATERIALS AND
METHODSThis is a review of a clinic registry of men with lower urinary tract symptoms secondary to benign
prostate hyperplasia who underwent HoLEP between August 2018 and January 2019. Patients
were assigned to group 1 (50 patients), group 2 (50 patients), and group 3 (50 patients) based on
the HoLEP being completed with either a Slimline 550mm, Slimline 1000mm, or MOSES
550 mm laser, respectively. The groups were compared using SSPS for ANOVA comparison of
means and multivariate logistic regression.RESULTS Ten patients who underwent concomitant stone surgery (2 PCNL, 8 ureteroscopy , 3 bilateral
cases) and 11 patients had bladder stones removed; ancillary procedures did not significantly differ
between groups(P = .2). Prostate enucleation times differed significantly (22.5 + 7.3, 16.4 + 6.9,
18.1 + 8.6 minutes P ≤.001) between groups. However, statistical significance was lost once enu-
cleation time was indexed against enucleated tissue weight. Time to achieve hemostasis (minutes)
was statistically different between groups (10.6 + 6.1, 7.7 + 5.2, 6.3 + 4.8 P <.001). This difference
in hemostatic time was maintained on multilogistic regression demonstrating that MOSES laser
enucleation was associated with a 3.9-minute decrease time to achieve hemostasis after enucle-
ation compared to Slimline 550 HoLEP (P <.001).CONCLUSION Our findings suggest that modulated pulsed laser energy can improve hemostasis during the enucle-
ation phase of a HoLEP resulting in shorter Operating Room times. UROLOGY 136: 196−201,
2020. © 2020 Elsevier Inc.5-7Holmium laser enucleation of the prostate (HoLEP)is a versatile surgical option for the treatment oflower urinary tract symptoms due to benign pros-
tate hyperplasia (LUTS/BPH).1-3 Multiple randomized con-
trol trials comparing HoLEP to alternate BPH procedures
have demonstrated short- and long-term safety, durability,
and symptom relief after HoLEP.4 Enucleation as a surgical
technique for the treatment of BPH has been safely per-
formed with a variety of energy sources including: bipolar
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Thlaser energy. Advancements in holmium laser technology
have been limited and have mostly been centered around
total power output by the laser units, however, modulated
pulsed laser energy in high powered units has been intro-
duced to optimize the efficacy of the laser. A specific exam-
ple of this innovation has been developed and distributed
by Lumenis as the MOSES laser platform. MOSES is a
unique laser pulse pattern that displaces any fluid between
the laser tip and target tissue allowing for more efficient
energy delivery to the biologic target. A software and hard-
ware upgrade to the Lumenis Pulse 120H system and single
use MOSES laser fibers are required to perform a MOSES
augmented HoLEP (m-HoLEP).
Despite HoLEP being heralded as the gold standard
therapy for LUTS/BPH,8 HoLEP only accounts for 5% of
surgical interventions in the United States.9 The most
cited hurdle to a more universal adoption of the surgical
technique is the learning curve associated with prostate
enucleation.10 Alternate surgical therapies include© 2020 The Authors. Published by Elsevier Inc.
is is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
transurethral resection of the prostate, Rezume, Urolift,
Aquablation, and robotic simple prostatectomy.11 In the
case of the surgical management of LUTS/BPH, HoLEP is
capable of treating symptomatic BPH in conjunction with
urolithiasis,2 independent of gland size,1 and in patients
on antiplatelet or anticoagulation (AP and/or AT)3 with
robust long-term symptom relief.12 The versatility and
durability of Holmium technology makes it an optimal
and cost-effective option for the surgical management
BPH. Further improvements in laser efficacy seen with
laser energy modulation offer the potential to improve
short-term outcomes, reduce the learning without
compromising long-term benefits of HoLEP.
Recent software engineering to modulate pulsed laser
energy and novel laser fibers have been developed in an
attempt to improve surgical performance of standard hol-
mium-based procedures such as ureteroscopy and HoLEP.
There is the hope that modulating laser energy might
improve short-term outcomes and potentially ease the
learning curve associated with surgery. After trialing the
MOSES system for HoLEP, we observed favorable hemo-
static properties during and after the enucleation process.
Increased hemostasis affords the surgeon better vision dur-
ing enucleation and morcellation and reduces the need
for continuous bladder irrigation to avoid postoperative
clot urinary retention. We sought to evaluation the effi-
ciency and hemostatic properties of the MOSES laser
technology (m-HoLEP), compared to standard laser tech-
nology (HoLEP) when utilized to perform a laser enucle-
ation of the prostate.METHODS
After IRB approval, a retrospective review of a prospectively
maintained clinical registry of men undergoing HoLEP was per-
formed. Between August 1, 2018 and Jan 31, 2019, 163 HoLEPs
were performed at a single center by a single surgeon (AK).
Because we are a tertiary referral center, 7 patients did not return
for their postoperative evaluation and 6 patients had a corrupted
laser log for peddle time and total laser energy used. Therefore
150 men were assigned to 3 groups based on whether their
HoLEP was performed using a 550 mm (group 1), 1000 mm
(group 2), or a 550 mm MOSES (group 3) fiber. The cases were
accrued in a consecutive fashion with m-HoLEP being the pre-
ferred option as fibers were available. During the 6 months when
a MOSES fiber was not available we would alternate cases with
550 and 1000 mm laser fibers. To keep cases consistent, all cases
were completed using a Lumenis MOSES Pulse compatible120H
dual peddle laser unit with maximal laser energy settings of 2 J
and 40 Hz. Despite having 120 W, we did not exceed 80 W
because of anecdotal evidence that the higher energy settings
can result in increased dysuria during the postoperative recovery.
Additionally, we learned that a narrow pulse width was benefi-
cial for laser dissection during standard HoLEP enucleation and
a widened laser pulse width with a lower energy setting of 1 J
and 20 Hz was better for hemostasis during m-HoLEP and
HoLEP. To minimize differences during the surgery, the same
hemostatic settings were used in all cases—in the case of m-
HoLEP, MOSES was disabled on the right (hemostatic) peddle.
Therefore, the only difference between the groups was thatUROLOGY 136, 2020MOSES was enabled when using the MOSES fiber during ade-
noma enucleation (left laser peddle), but disabled with the
incompatible 550 and 1000 mm Slimeline SIS laser fibers.
By assigning the left foot peddle of the laser with cutting set-
tings and the right peddle with hemostatic settings mentioned
above, we could track the absolute time used to dissect the ade-
noma and to achieve hemostasis within the prostatic fossa. In
all cases, HoLEP was completed in a standard 2 or 3 lobe, bot-
tom-up, enucleation fashion with reduction in laser energy to
40 W (2 J and 20 Hz) during the apical turn near the sphincter
complex, but otherwise maintained at 80 W (2 J and 40 Hz).13
During prostate enucleation, bleeding vessels were cauterized
using the right, hemostatic, peddle. Prior to prostate morcella-
tion, the prostatic fossa was inspected and all bleeding vessels
and surfaces were cauterized using the hemostatic peddle. This
is our standard practice to optimize visualization during morcel-
lation and help prevent bleeding related complications in the
postoperative setting. Bladder stones too large to be evacuated
through the 28-Fr resectoscope sheath were fractured with laser
settings of 1 J and 30 Hz prior to prostate enucleation. Any
other stone procedures were performed after the HoLEP was
completed and data from this portion of the procedure was not
included in the final laser analysis. At the conclusion of the
case, the case registry log on the holmium laser unit was down-
loaded to a USB-drive. This data contained the absolute time
of left and right peddle usage (minutes) and total used laser
energy (kilojoules).
General demographics, patient symptom scores, retention sta-
tus, perioperative outcomes, and 90-day complications were
compared between the groups with a chi-squared analysis or an
ANOVA comparison of means. Approximately 7 days after sur-
gery our nursing staff contacted the patient to discuss pathology
results and to assess for any concerning symptoms; specifically,
the patients were questioned regarding persistent dysuria after
surgery. AUA symptom scores and voiding metrics using a uro-
flow and bladder scanner were obtained at a 3-months post-
HoLEP clinic appointment. Provided the patients had no clini-
cal findings of a urinary tract infection or recent catheterization,
a PSA blood test was obtained. Patients with incidental prostate
cancer on their HoLEP specimen, a PSA greater than
1.5 ng/mL, persistent incontinence, or who requested, were pro-
vided a second follow-up appointment at 6 months. The remain-
ing patients were released back to their referring providers.
Patients who did not present to clinic were mailed a BPH packet
that contained an International Prostate Symptom Score, Mich-
igan Incontinence, and Sexual Health Inventory for Men scores.
Complications up to 90 days postoperatively were evaluated by
using the electronic medical record. The Clavien-Dindo classifi-
cation system was used to categorize the complications.
Intraoperative evaluation of enucleation time (minutes) asso-
ciated with specific fiber usage was controlled for with prostate
gland size. To understand patient and intraoperative factors that
influence time to achieve hemostasis, we performed a multiple
linear regression model, adjusted for specimen size, patient age,
and AT status, and type of fiber used to perform the procedure.
Statistics were performed by a single statistician using JMP statis-
tical software.RESULTS
During the study period, 150 patients were included for analysis.
Table 1 outlines the basic demographics between groups. There197
Table 1. Preoperative characteristics
Slimline 550 Slimline 1000 MOSES 550 P
50 50 50
Age 71 § 8.2 70.3 § 8.8 72 § 9.0 .91
BMI 27.7 § 5.3 27.9 § 4.3 28 § 5.9 .45
Prostate size 110.5 § 85.5 118.3 § 92.4 155.6 § 50.3 .56
Pre-Op PSA 5.86 § 4.8 8.59 § 12.2 8.39 § 5.9 .44
Pre-Op serum creatinine 1.34 + 1.1 1.34 + 1.7 1.16 + 0.4 .67
Urinary retention 22 (44%) 19 (38%) 16 (31%) .47
Prior prostate biopsy 16 (32%) 16 (32%) 19 (36.5%) .91
Hx of prostate cancer 1 (2%) 4 (8%) 4 (7.7%) .63
Prior BPH surgery (Ave No.) 10 (1.2) 4 (1.3) 7 (1.4) .11
Hx or urinary tract infections 5 (10%) 4 (8%) 4 (8%) .91
Preoperative incontinence 10 (20%) 6 (12%) 6 (11%) .89
Diabetes mellitus 7 (14%) 4 (8%) 9 (17%) .41
Alpha-blocker 34 (68%) 40 (80%) 37 (71.2%) .39
5-Alpha-Reductase Inhibitor 15 (30%) 8 (16%) 11 (21%) .27
ASA score I 0 1 (2%) 0
II 17 (34%) 8 (16%) 9 (17%)
III 33 (66%) 39 (78%) 41 (79%)
IV 0 2 (4%) 2 (4%) .22
Antiplatelets/coagulants 15 (30%) 12 (24%) 15 (29%) .83
Discontinue/bridged/continue 9/4/2 10/1/1 9/5/2
Concomitant stone surgery 4 (8%) 5 (10%) 1 (1.9%) .41
Concomitant cystolitholopaxy 5 (10%) 5 (10%) 1 (1.9%) .23
Enucleation time (min) 47.1 § 17.9 41.5 § 14.6 40.9 § 15.1 .01
Laser cutting time (min) 22.5 § 7.3 16.4 § 6.9 18.1 § 8.6 <.001
Hemostasis time (min) 10.6 § 6.1 7.7 § 5.2 6.3 § 4.8 <.001
Morcellation time (min) 11.6 § 10.9 10.2 § 13.5 10.3 § 13.4 .68
Ave [range] Operating Room specimen Wt (g) 72.5[3-265] 65.9[4-315] 76.7[4-448] .71
Change in Hgb (mg/dL) 1.5 + 1.2 1.5 +1.6 1.0 + 1.1 .02
Same day discharge 0 4 3 .02
Void and discharge within 24 hours 46 (92%) 41 (89%) 45 (92%) .74were no differences in age, comorbidities, American Society of
Anesthesia physical status classification, BPH medication, or AP
and/or AT status between the groups. There were 10 patients
who underwent concomitant stone surgery (2 PCNL, 8 uretero-
scopy , 3 bilateral cases) and 11 patients had bladder stones. Of
note only 2 cases required lasering for the cystolithalopaxy
(Table 1). Of the cohort, 57 men (38%) were in urinary reten-
tion and 42 (28%) were on AP and/or AT that required bridging
in most cases (Table 1).
Intraoperative enucleation times (P = .01) and cutting peddle
utilization times were significantly less (P <.001) between the
groups. However, statistical significance was lost once these
times were indexed against enucleated tissue weight. The vol-
ume of prostate adenoma enucleated ranged from 8 to 488 g
with no statistical difference between the mean grams enucle-
ated in each group (72.5 § 49.6, 65.9 § 63.6, 76.7 § 77.1, for
groups 1, 2, and 3, respectively; P = .7). Time to achieve hemo-
stasis (minutes) (ie, use of the right peddle) was statistically
different between the different groups (10.6 § 6.1, 7.7 § 5.2,
6.3 § 4.8 P <.001).
Averaging the postoperative changes in hemoglobin com-
pared to the baseline hemoglobin showed statistical difference
between the MOSES group and the other 2 groups (Group 1
was 1.5 § 1.2, Group 2 was 1.5 § 1.6, Group 3 was 1.0 § 1.1
4mg/dL; P ≤.02); however, the clinical relevance of the
observed difference is somewhat limited. There were 145
patients admitted as an outpatient in a bed with 91% discharging
home in less than 24 hours without a catheter. There were 7
patients (4.6%) who required a single in-and-out catheterization
and then voided spontaneously and 4 (2.6%) required a catheter198at discharge with 100% removal within 72 hours. Two patients
had a prolonged hospital stay, the first of which had a myocardial
infarction prior to HoLEP requiring AP and/or AT causing clot
urinary retention that was remedied with a bed side irrigation
(Clavien IIIa-group 2). The second patient had a prolonged pre-
surgical hospitalization and was originally admitted with urinary
retention, bacteriuria, and bacteremia prior to HoLEP. The
patient required a 48-hour post m-HoLEP stay because of decon-
ditioning. Nine (5.9%) patients experienced a complication
within 90 days of surgery (Table 2). In addition to the above-
mentioned patient who required a bed side clot evacuation
(IIIa), there was a single patient in group 1 who restarted his
third generation AT 2 days after discharge went into clot urinary
retention requiring an anesthetic and clot evacuation (IIIb).
Four other patients presented to the emergency room with
hematuria requiring reassurance (2 patients—Clavien I) and a
urinary tract infection requiring antibiotics (Clavien II). There
were no transfusions, no intensive care admission, and no deaths
in this study.
The average follow-up for the group was 13.7 + 1.6 weeks with
78% of patients presenting to their 3-month postoperative clinic
appointment. All patients who do not present for follow-up were
mailed a questionnaire packet with the same metrics they com-
pleted preoperatively. Postoperatively, there were no differences
in rates of dysuria beyond 2 weeks, voiding function or urinary
quality of life scores between the groups (Table 2). Average reduc-
tion in AUA symptom scores ranged from 12.5 to 13.5§ 3.3 with
the group 3 patients having the most pronounced improvement of
5.5 § 4.6 (P = .01). Incontinence rates were measured with the
Michigan Incontinence Symptom Index and were equivalentUROLOGY 136, 2020
Table 2. Postoperative outcomes
Slimline 550 Slimline 1000 MOSES 550 P
Average f/u [wk]/No. of patients 14.8 + 6.1 [38] 14.7 + 5.1 [42] 14.4 + 5.2 [39] .8
Pre-Op AUAss (Mean/Median) 21/20 20/21 19/18 .2
Post-Op AUAss (Mean/Median) 7.5/6.5 6.5/6.5 5.5/2.5 .01
Post-Op MISI Score (Mean/Median) 7.5 + 7.8 10.5 +7.2 8.9 + 6.9 .1
Post-Op MISI Bother (Mean/Median) 0.65 + 1.4 1.02 + 1.2 0.73 + 1.1 .5
Post-Op Quality of life 1.2 + 1.2 1.1 +1.6 1.9 + 1.1 .4
Post-Op max flow rate 21.7 + 5.5 20.5 + 9.6 22.1 + 10.8 .2
Post-Op average flow rate 15.8 + 9.4 14.7 + 5.5 19.1 + 7.1 .2
Post-Op post void residual 95.4 + 101.3 59.8 + 42.8 62 + 59.9 .4
Post-Op PSA 1.5 + 1.4 0.7 + 0.5 0.8 + 0.8 .4
Did not void and discharge <24 h .8
Voiding issues 4 (8%) 4 (8%) 3 (5.7%)
Prolonged Length of stay 0 1 (2% - Clavien IIIa) 1 (1.9%)
Incontinence at 3 mo 1 (2%) 1 (2%) 2 (1.3%) .6
Dysuria beyond 2 weeks post-op 0 3 (6%) 1 (1.9%) .2
Emergency room visit 2 (4%) 1 (2%) 1 (1.9%) .5
Clavien-Dindo classification I 1 (2%) 1 (2%) 0
II 1 (2%) 2 (4%) 2 (3.8%)
III 1 (2%) 1 (2%) 0
90-day complications 3 (6%) 4(8%) 2 (1.3%) .4
MISI, Michigan Incontinence Symptom Index.between all 3 groups (Table 2). There were 5 patients with new
persistent incontinence based on Michigan Incontinence Symp-
tom Index (Table 2) of which, 4 followed up at 6 months after fur-
ther pelvic floor and additional anticholinergic therapy with
resolution of their incontinence.
To better understand the relationship between specific fiber
usage and the time required to achieve hemostasis, we performed
a multilogistic regression. This was of particular interest given
the same laser energy settings of 1 J and 20 Hz with a wide pulse
width was assigned to the right peddle in all 3 groups. The
550 mm laser fiber was established as the standard case to evalu-
ate the effects of patient age, preoperative presence of a urinary
catheter, AP and/or AT status, and use of the SIS 1000 or
MOSES 550 fiber on the time required to achieve hemostasis.
Based on the logistic regression, fiber type independently
affected time to achieve hemostasis with MOSES having the
greatest affect (3.9-minute decrease hemostatic peddle time)
compared to the Slimline 550 HoLEP (P <.001—Table 2). This
suggests that during enucleation m-HoLEP is more hemostatic
and requires less time to achieve hemostasis after enucleation.
This was more evident as prostate volume, shown to increase
time to achieve hemostaisis (Table 3), had less affect when using












This table represents the multilogistic regression for variables that aff
fiber with time affects (minutes) to achieve hemostasis expressed via
the null value.
UROLOGY 136, 2020DISCUSSION
This is the first comparative study, to our knowledge, of a
modified pulsed holmium laser system used to enhance
HoLEP. Intraoperatively, we noted a significant decrease
in enucleation time and hemostasis time with the MOSES
system, with persistent decrease in hemostasis time after
multivariate analysis (Table 3). This multivariate analysis
suggests that for every 10-g increase in prostate gland size,
there is approximately a 40% increase in time to achieve
hemostasis with a standard 550 micron fiber; this is
reduced 3.9-fold when using pulse modulated laser tech-
nology and a MOSES 550-fiber. These benefits are modest
but with further improvements in the energy modulation,
along with further development in laser fiber technology,
a more clinically significant impact is likely to occur.
Demonstrating improved hemostasis can be challenging.
With m-HoLEP we noted a significantly smaller decrease
in hemoglobin from preoperative levels, and while this
has a limited clinical impact, it does help support the
added hemostatic potential of a modified pulsed laser
energy. Furthermore, standard outcomes such as changeo achieve hemostasis
95% CI (min) P Value
− −
3.48 to 0.71 .003
5.26 to 2.53 <.001
0.55 to 2.19 .238
0.03 to 0.11 .290
0.43 to 1.12 .222
0.52-0.70 <.001
ect time to achieve hemostasis. The control was a 550 mm laser
95% confidence interval (CI). Only fiber type and gland size exclude
199
Figure 1. This is a graph demonstrating the inverse relationship of gland size (g) to time to achieve hemostasis (minutes)
stratified by laser fiber. The green line represents 550 MOSES fiber enucleation. The slope of the line is a surrogate for
hemostatic efficiency. The flatter the line the more hemostatic the enucleation process. (Color version available online.)in symptom scores, flow rates, incontinence, and dysuria
were no different among groups.
The MOSES effect was first described in 1986 but was
not optimized for clinical use in urology until 2017 with
the release of the MOSES technology by Lumenis. The
specific wavelength (~2.1 mm) of holmium laser energy is
highly absorbent and dissipates easily within water. The
MOSES laser system modulates the pulsed laser energy to
create an initial vapor bubble, which displaces any fluid
between the target and laser tip. At the same time a vapor
tunnel is created, through which, subsequent laser energy
can pass with low attenuation delivering the maximal
energy to the target.14 The first application of MOSES
technology was for the treatment of nephrolithiasis.15,16
Given the overlap in patients, providers and technologies
for surgical stone and BPH treatment, the use of MOSES
technology for HoLEP was a natural progression. In our
experience, while we endorse that there are modest clini-
cal differences between m-HoLEP and standard HoLEP,
we do feel that MOSES technology can be safely imple-
mented into a HoLEP practice and potentially improve
the surgical experience.
m-HOLEP builds on a robust surgical technique with
exceptional short- and long-term outcomes to further opti-
mize on specific goals of BPH surgery; namely hemostasis.17
The interaction between the laser fiber and prostate tissue
is critical for efficiency and completeness of the enucle-
ation. The objective of HoLEP is to quickly identify the200surgical capsule, stay within the surgical plane, and main-
tain hemostasis throughout the case.18 Obscured planes
from tissue charring19 or a heavy reliance on mechanical
enucleation with the cystoscope can prolong surgery,
increase hematuria and murky vision, and can result in
postoperative bleeding complications. We observed a favor-
able when performing m-HoLEP. Group 3 had 15% faster
enucleation, 40% faster hemostatic times, and was less
affected by increases in prostate gland size (Fig. 1). This is
the first application of a modified pulsed holmium laser
energy applied to prostate enucleation, and even though
the results are modest, we do feel there is value in using m-
HoLEP for surgical BPH therapy. The improvements in
hemostasis could potentially help the novice surgeon over-
come the learning curve by improving vision clarity.
A major concern with the adoption of procedures
requiring new technology is the cost associated with
equipment upgrades. In a cost savings approach many
urologists are utilizing a lower powered holmium laser,
typically used for stones, to perform HoLEP for LUTS/
BPH.20 Even though low power enucleation of the pros-
tate is feasible, there are many benefits, outlined in this
paper, to using a high-powered laser system. One of the
largest impacts on overall cost of care is reducing the need
for a hospital stay after surgery. In one study, day-case
HoLEP was successful in 83.4% of same day HoLEPs with
all failed cases stemmed from urinary bleeding.21 Utilizing
a laser that is associated with improved hemostasis canUROLOGY 136, 2020
improve the chances of a successful outpatient BPH prac-
tice. In this study we demonstrated that increasing pros-
tate size, which increases bleeding (Table 3) and delays
time to achieve hemostasis is reduced when performing
m-HoLEP (slope of green line—Fig. 1). These findings
could help the advanced surgeon transition to a consistent
outpatient HoLEP practice.
This publication is not without limitations. It is a retro-
spective review of a single center, single surgeon experi-
ence and may not be applicable to all hospital systems.
Patients were not prospectively randomized, but rather
were enrolled in a contiguous fashion. With this study
model, there may be concerns that the surgeon improved,
or the surgical technique evolved during the study, which
resulted in the better hemostasis. However, the study rep-
resents a 6-month period in a 10-year history of perform-
ing HoLEP by a single surgeon. There are resident and
fellow involvement in the enucleation portion of the pro-
cedure, however, the task of achieving hemostasis after
enucleation is complete is performed exclusively by the
staff surgeon. This supports the improved hemostatic
properties of the modulated pulsed laser energy. There-
fore, we feel that it is a reasonable conclusion that the
evolution in laser technology is positively affecting the
procedure. Additional work is needed to better character-
ize the extent to which this technology is responsible for
achieving hemostasis and what further advances in this
field may yield for the procedure. There were 10 patients
who had concomitant stone surgery, but this did not affect
the analysis as division of the case was achieved by select-
ing only times the 550-micron laser fiber was in use. Long-
term data regarding the effects of MOSES laser technology
is limited; however, given the favorable 3 months data
and identical surgical technique we expect similar out-
comes such as s-HoLEP after 10 years.12 Despite these lim-
itations, this study is the first to demonstrate improved
efficiency and hemostasis of HoLEP performed with a
pulse modulating holmium system and optimized laser
fiber technology.CONCLUSION
Using modulated pulsed holmium laser energy to enhance
prostate enucleate is safe and effective. This study used
the MOSES platform by Lumenis to generate a modified
pulsed laser energy, however, there are other platforms
emerging with pulsed-modulated laser technology. m-
HoLEP was increased Operating Room efficiency and
hemostasis regardless of prostate size compared to s-
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